Skip to main content

Table 3 Survival analysis demonstrating association between age, PSA, cT, GS and BSIduring ADT

From: Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy

Variable at follow-up N Hazard ratio pvalue
Univariate analysis    
Age 146 1.04 (1.004 to 1.07) 0.03
PSA 146 1.0002 (1.00002 to 1.0003) 0.03
TS 131 2.39 (1.41 to 4.04) 0.001
GS 135 1.75 (1.32 to 2.32) 0.0001
BSI 146 1.26 (1.18 to 1.35) <0.0001
Multivariate analysis    
Age 121 1.04 (1.0004 to 1.08) 0.03
PSA 121 1.0006 (1.0003 to 1.0009) <0.0001
TS 121 2.09 (1.24 to 3.51) 0.006
GS 121 1.70 (1.23 to 2.35) 0.001
Multivariate analysis    
Age 121 1.05 (1.01 to 1.09) 0.009
PSA 121 1.0004 (1.00001 to 1.0008) 0.04
TS 121 1.98 (1.21 to 3.24) 0.007
GS 121 1.47 (1.04 to 2.08) 0.03
BSI 121 1.19 (1.09 to 1.29) <0.0001
  1. PSA, prostate-specific antigen; cT, clinical stage; GS, Gleason score; BSI,Bone Scan Index; ADT, androgen deprivation therapy; N, number of patients.